Summary
Carvedilol, a novel β-blocker with a vasodilating action, was given either alone (monotherapy) or with diuretics (combination therapy) to 42 patients with renal hypertension. The hypotensive effect, safety, and optimal dose were investigated. In all, 23 untreated patients (16 men and 7 women; average age, 56.4 ± 2.5 years) made up the monotherapy group and 19 diuretic-treated patients (11 men and 8 women; average age, 56.4 ± 2.5 years) comprised the combined therapy group. All subjects had an initial blood pressure (BP) of > 160/95 mmHg and were started on 5 mg/day oral carvedilol. The dose was gradually increased to a maximum of 20 mg/day, or until either the BP was reduced to < 149/89 mmHg or the reduction in mean BP was > 13 mmHg compared with baseline levels. The total study period was 8 weeks. With monotherapy, the BP and heart rate decreased significantly from 167/102 to 150/94 mmHg and from 81 to 74 beats/min, respectively. With combined therapy, the BP and heart rate fell significantly from 176/103 to 142/85 mmHg and from 81 to 70 beats/min, respectively. Responders were defined as subjects with a BP of ⩽ 149/89 mm Hg or those showing a fall of ⩽ 13 mmHg in mean BE Responders accounted for 52.2% of the monotherapy group and 73.6% of the combination therapy group. Orthostatic hypotension was not seen in either group. Serum creatinine and blood urea nitrogen (BUN) levels were not altered by administration of carvedilol. Dizziness was noted by 1 of the 23 subjects in the monotherapy group. These results suggest that carvedilol is an effective and well-tolerated antihypertensive agent for the management of renal hypertension. We considered the optimal dose to be from 10 to 20 mg once daily, which is similar to that recommended for essential hypertension.
Similar content being viewed by others
References
Prichard BNC, Owens CWI (1984) Clinical pharmacology of beta-adrenoceptor blocking drugs. In: Kostis JB, Felice EA de (eds) Beta blockers in the treatment of cardiovascular disease. Raven Press, New York, pp 1–56
Prichard BNC (1983) Mechanisms of myocardial infarct prevention with beta-adrenergic blocking drugs. Drugs 25 [Suppl 2]: 295–302
O'Brien ET, MacKinnon J (1972) Propranolol and polythiazide in treatment of hypertension. Br Heart J 34: 1042–1051
De Leeuw PW, Birkenhäger WH (1983) Renal effects of beta blockade in essential hypertension. Eur Heart J 4 [Suppl D]: 13–17
Wilkinson R (1982) Beta-blockers and renal function. Drugs 23: 195–206
Sponer G, Bartsh W, Strein K, Müller-Beckman B, Böhm E (1987) Pharmacological profile of carvedilol as a β-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol 9: 317–326
Irie K, Takasuna K, Kunitada S, Mori T, Ashida S (1987) Hemodynamic profile of carvedilol, a new β-adrenoceptor blocking agent with vasodilating properties in conscious SHR. Jpn J Pharmacol 43 [Suppl]: 142
Tamaki T, Hasui K, Yamamoto A, Aki Y, Shoji T, Nakamura A, Kimura S, Fukui K, Iwao H, Abe Y (1988) Renal vasodilatory action of carvedilol. Drugs 36 [Suppl 6]: 155–159
Neugebauer G, Akpan W, Möllendorff E, Neubert P, Reiff K (1987) Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol 10 [Suppl 11]: S85-S88
Kohno M, Takeda T, Ishii M, Saruta T, Mizuno Y, Yoshimura M, Kubo S, Fukiyama K, Fujishima M (1988) Therapeutic benefits and safety of carvedilol in renal hypertension. An open, shortterm study. Drugs 36 [Suppl 6]: 129–135
Cubeddu LX, Fuenmayor N, Varin F, Villagra VG, Colindres RE, Powell JR (1987) Mechanism of the vasodilatory effect of carvedilol in normal volunteers: a comparison with labetalol. J Cardiovasc Pharmacol 10 [Suppl 11]: S81-S84
Dupont AG, Van der Niepen P, Taeymans Y, Ingels M, Piepsz A, Bossuyt AM, Block P, Six OR, Jonckheer MH, Vanhaelst L (1987) Effect of carvedilol on ambulatory blood pressure, renal hemodynamics and cardiac function in essential hypertension. J Cardiovasc Pharmacol 10 [Suppl 11]: S130-S136
Kohno M, Murakawa K, Okamura M, Yasunari K, Yokokawa K, Horio T, Inoue T, Takeda T (1988) Effects of long term administration of carvedilol on renal haemodynamics and functions in DOCA salt-induced accelerated hypertension of spontaneously hypertensive rats. Drugs 36 [Suppl 6]: 165–168
Nakamoto H, Suzuki H, Katsumata H, Ohishi A, Saruta T, Sakaguchi H (1988) Effects of carvedilol on renal function and blood pressure in three-fifths nephrectomized spontaneously hypertensive rats loaded with high salt. Drugs 36 [Suppl 6]: 160–164
Hakusui H, Fujimaki M (1988) Pharmacokinetics of carvedilol in hypertensive patients with renal failure. Drugs 36 [Suppl 6]: 144–147
Ikeda M, Aoki K, Arakawa N, Inagaki Y (1979) Clinical efficacy of Diltiazem (Herbesser) in patients with essential hypertension — a placebo-controlled double-blind comparative study. Igaku No Ayumi 100: 302–320
Ohshima K, Goto Y, Masuyama Y, Kajiwara N (1979) Clinical evaluation of prazosin in patients with essential hypertension. Igaku No Ayumi 108: 186–201
Ikeda M, Masuyama Y, Yoshinaga H, Inagaki Y, Ishii T (1986) Clinical efficacy of amosulalol (YM-09538) in patients with essential hypertension. Igaku No Ayumi 139: 425–453
Ogihara T, Goto Y, Yoshinaga K, Kumahara Y, Iimura O, Ishii M, Murakami E, Takeda T, Kokubu T, Arakawa K, Ikeda M (1988) Dose-effect relationship of carvedilol in essential hypertension. An open study. Drugs 36 [Suppl 6]: 75–81
Yasujima M, Goto Y, Yoshinaga K, Kumahara Y, Iimura O, Ishii M, Murakami E, Takeda T, Kokubu T, Arakawa K, Ikeda M (1988) Efficacy and tolerance of carvedilol in combination with a thiazide diuretic in the treatment of essential hypertension. An open study. Drugs 36 [Suppl 6]: 118–123
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takeda, T., Kohno, M., Ishii, M. et al. Efficacy and safety of carvedilol in renal hypertension. Eur J Clin Pharmacol 38 (Suppl 2), S158–S163 (1990). https://doi.org/10.1007/BF01409488
Issue Date:
DOI: https://doi.org/10.1007/BF01409488